SNY vs. VRTX, BMY, REGN, PFE, GSK, ZTS, ABT, NVS, TAK, and BIIB
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Pfizer (PFE), GSK (GSK), Zoetis (ZTS), Abbott Laboratories (ABT), Novartis (NVS), Takeda Pharmaceutical (TAK), and Biogen (BIIB). These companies are all part of the "medical" sector.
Vertex Pharmaceuticals (NASDAQ:VRTX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Vertex Pharmaceuticals presently has a consensus price target of $429.45, suggesting a potential upside of 8.04%. Sanofi has a consensus price target of $55.00, suggesting a potential upside of 11.95%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Sanofi is more favorable than Vertex Pharmaceuticals.
91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Sanofi shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Vertex Pharmaceuticals and Vertex Pharmaceuticals both had 21 articles in the media. Sanofi's average media sentiment score of 0.67 beat Vertex Pharmaceuticals' score of 0.45 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.
Vertex Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Sanofi has higher revenue and earnings than Vertex Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals received 1514 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Vertex Pharmaceuticals' net margin of 10.52%. Sanofi's return on equity of 21.91% beat Vertex Pharmaceuticals' return on equity.
Summary
Vertex Pharmaceuticals beats Sanofi on 12 of the 17 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools